NCT05255666View on ClinicalTrials.gov

Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)

PHASE2WithdrawnINTERVENTIONAL

Timeline

Start Date

July 31, 2023

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2030

Conditions

Triple Negative Breast CancerBrain Metastases

Interventions

DRUG

Pembrolizumab

400 mg intravenously

DRUG

Liposomal Irinotecan

Starting at 50 mg/m\^2. The dose may be increased to 70 mg/m\^2 if tolerated or dose reduced to 35 mg/m\^ if treatment-emergent severe adverse event (TESAE) occurs.